The Pharma world is seeing a big opportunity in GLP-1s – the new innovative fast emerging drugs for diabetes & obesity. Kiran ...

Nevertheless, European companies have found themselves in the sights of America’s president, who is irked by the fact that ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

AbbVie ABBV stock has declined 12.6% in the past three months. The stock is also trading below its 50-day and 200-day moving ...

AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside.

How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created ...

Internationally, the scale is far smaller. There is not a single public company outside the US currently worth $1 trillion.

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Denmark’s exports will grow clearly less than expected earlier, partly due to the setbacks Novo Nordisk A/S is facing in the ...